Our research into rare cancers
Our strategy
For the past 120 years, we’ve been making discoveries that have saved countless lives. But we have so much more to do. Our strategy sets out how we'll accelerate progress towards a better future.
Our research is saving lives
Together, rare cancers make up more than 20% of all cancer cases. We’ve contributed to several advances for people with rare cancers. We ran some of the first trials for people with uveal melanoma and neuroendocrine tumours, and showed that the drug Glivec was effective for some advanced gastro-intestinal stromal tumours (GIST). And we set up and continue to support the International Rare Cancers Initiative, which is developing clinical trials worldwide to find new treatments for rare cancers.
Current research
From studying the biology of rare cancer cells in the lab to leading clinical trials testing cutting-edge treatments, our researchers are working hard to ensure more people survive rare cancers.
Past research
Thanks to research, we’ve helped change the outlook for people with rare cancers.
Patients' stories
Meet people like Oliver who have experienced first-hand how our research is making a difference. The life-saving research we do wouldn’t be possible without your support.
Cancer news
From cutting edge science and debunking myths to patient stories, read the latest news, analysis and opinion on our news site.
Further information
Our strategy
Over the last 40 years, cancer survival in the UK has doubled. In the 1970s just 1 in 4 people survived their disease for 10 years or more. Today 2 in 4 survive.
We want to accelerate progress and see 3 in 4 patients surviving the disease by 2034.